Clinical Chemistry, Vol 35, 234-237, Copyright © 1989 by American Association for Clinical Chemistry

A two-site immunoenzymometric assay of 52-kDa pro-cathepsin D, and its use in human breast diseases

G Freiss, F Vignon, B Pau, F Paolucci and H Rochefort
Institut National de la Sante et de la Recherche Medicale, Unite Hormones and Cancer (U 148), Montpellier, France.

After isolating monoclonal antibodies specific for the 52-kDa precursor of cathepsin D (cath-D), which is secreted in excess in both hormone- dependent and hormone-independent breast cancer, we developed a two- step double-determinant immunoenzymometric assay that is specific for this pro-enzyme. The assay combines the use of a monoclonal antibody specific for the precursor and bound to microtiter plates, and a second antibody directed against a smaller processed form of the mature enzyme, coupled to alkaline phosphatase. The specificity of the assay relies on separate and sequential additions of the antigen and the conjugated second antibody. It allows rapid measurement of the analyte in plasma and cytosols of normal and neoplastic mammary tissues, with a detection limit of 5 fmol and a maximal interassay coefficient of variation of 9%. This assay is particularly useful for tissue cytosol samples where the pro-enzyme form co-exists with large quantities of the mature processed forms of the enzyme. Comparative assays of 52-kDa pro-cath-D and total cath-D in cytosols of breast cancers and benign mastopathies indicate that the present assay better discriminates between benign and cancerous mammary tumors.